FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	DVAL				
OMB Number:	3235-0287				
Estimated average burd	len				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Jooste H Le Roux</u>							2. Issuer Name and Ticker or Trading Symbol NABI BIOPHARMACEUTICALS NABI									eck all ap Dire		ng Person(s) to I		
(Last) (First) (Middle) C/O NABI BIOPHARMACEUTICALS 5800 PARK OF COMMERCE BLVD., N.W.							3. Date of Earliest Transaction (Month/Day/Year) 11/04/2005									belo)``	
(Street) BOCA RATON FL 33487 (City) (State) (Zip)						4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)) <mark>X</mark> Fori Fori	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date					2. Transa Date (Month/D	Execution Date,			Transaction Disposed Code (Instr. 5)			ties Acquired (A) I Of (D) (Instr. 3,			Secui Benef Owne	ficially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
											v	Amount	() (I	A) or O)	Price		action(s) 3 and 4)		(Instr. 4)	
Common	Stock			11/04/2005 P 10,000 A \$3.55 10,000 D																
			Та									sed of, onvertib				Owned	I			
1. Title of Derivative Security (Instr. 3) 2. Conversion Exercion Price of Derivative Security		on ise	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. B)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date	on Dat		Amount of Securities Underlying Derivative Security (Instr. and 4) Amount of Medical Security (Instr. and 4)		str. 3	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

Remarks:

/s/ James E. Dawson, as attorney-in-fact

11/08/2005

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.